StockIQpro
NASDAQ:IDYA

IDEAYA Biosciences, Inc.

Track all markets on TradingView
Track all markets on TradingView

IDEAYA Biosciences, Inc.'s revenue grew 3024.4% in fiscal 2025 to $218.7M while operating margin rose to −72.8%, its highest in 6 years. Free cash flow was −$73.5M, −33.6% of revenue, and the diluted share count rose 8.3%.Summary generated from IDEAYA Biosciences, Inc.'s SEC filings. Latest annual report filed Feb 17, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$218.7M
Revenue growth+3024.4%
Revenue, 5-yr CAGR+62.1%
Gross marginn/a
Operating margin−72.8%
Net margin−52.0%
ROICn/a
Return on equity−10.9%
Debt / equityn/a
Free cash flow−$73.5M
FCF margin−33.6%
Share count change+8.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue2851237219
Operating income−50−63−134−327−159
Net income−50−59−113−274−114
Free cash flow−58−91−118−251−73

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations